Eptifibatide

BreastfeedingPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Anticoagulants, Antiplatelet agents, Collagenase, Dasatinib, Drotrecogin Alfa, Fondaparinux, Glucosamine, Ibritumomab, Iloprost, Lepirudin, NSAIDs, Pentoxifylline, Salicylates, Thrombolytic agents, Tositumomab & Iodine131

PREGNANCY CATEGORY: B

Contra-indicated in patients with a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days; severe hypertension not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; history of stroke within 30 days or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb/IIIa inhibitor; or dependency on renal dialysis.

Our database has 9 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
HEMATOLOGIC.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of eptifibatide in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top